Collins Stewart initiates coverage on Alexion Pharmaceuticals (Nasdaq: ALXN) with a Buy rating and $95 price target.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE